{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT01835197",
      "orgStudyIdInfo": {
        "id": "B7451001"
      },
      "organization": {
        "fullName": "Pfizer",
        "class": "INDUSTRY"
      },
      "briefTitle": "First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects",
      "officialTitle": "A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects"
    },
    "statusModule": {
      "statusVerifiedDate": "2014-06",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2013-05"
      },
      "primaryCompletionDateStruct": {
        "date": "2014-06",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2014-06",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2013-04-15",
      "studyFirstSubmitQcDate": "2013-04-15",
      "studyFirstPostDateStruct": {
        "date": "2013-04-18",
        "type": "ESTIMATED"
      },
      "lastUpdateSubmitDate": "2014-06-19",
      "lastUpdatePostDateStruct": {
        "date": "2014-06-20",
        "type": "ESTIMATED"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Pfizer",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": false
    },
    "descriptionModule": {
      "briefSummary": "This single- and multiple-ascending dose study is the first evaluation of PF-04965842, a Janus kinase1 (JAK1) inhibitor, in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Western and Japanese subjects."
    },
    "conditionsModule": {
      "conditions": [
        "Healthy"
      ],
      "keywords": [
        "Phase 1",
        "Randomized",
        "Double Blind",
        "Placebo-Controlled",
        "Single- & Multiple Dose Escalation",
        "Safety",
        "Tolerability",
        "PK",
        "PD",
        "Pf-04965842"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "BASIC_SCIENCE",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 79,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "SAD Cohorts 1-8 Experimental Arm",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: PF-04965842"
          ]
        },
        {
          "label": "SAD Cohorts 1-8 Placebo Arm",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        },
        {
          "label": "MAD Cohorts 3 through 5 Experimental Arm",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: PF-04965842"
          ]
        },
        {
          "label": "MAD Cohorts 3 through 5 Placebo Arm",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        },
        {
          "label": "MAD Cohorts 6 and 7 Experimental Arm",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: PF-04965842"
          ]
        },
        {
          "label": "MAD Cohorts 6 and 7 Placebo Arm",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        },
        {
          "label": "MAD Cohort 8 Experimental Arm",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: PF-04965842"
          ]
        },
        {
          "label": "MAD Cohort 8 Placebo Arm",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        },
        {
          "label": "MAD Cohort 9 Experimental Arm",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: PF-04965842"
          ]
        },
        {
          "label": "MAD Cohort 9 Placebo Arm",
          "type": "PLACEBO_COMPARATOR",
          "interventionNames": [
            "Drug: Placebo"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "PF-04965842",
          "description": "Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.",
          "armGroupLabels": [
            "SAD Cohorts 1-8 Experimental Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.",
          "armGroupLabels": [
            "SAD Cohorts 1-8 Placebo Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "PF-04965842",
          "description": "Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohorts 3 through 5 Experimental Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohorts 3 through 5 Placebo Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "PF-04965842",
          "description": "Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohorts 6 and 7 Experimental Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohorts 6 and 7 Placebo Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "PF-04965842",
          "description": "Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohort 8 Experimental Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohort 8 Placebo Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "PF-04965842",
          "description": "Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohort 9 Experimental Arm"
          ]
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": "Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.",
          "armGroupLabels": [
            "MAD Cohort 9 Placebo Arm"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Changes from baseline vital signs (blood pressure, pulse rate, oral temperature and respiration rate) and physical examinations",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Changes from baseline in 12 lead ECG parameters",
          "description": "Quantitative changes in ECG intervals",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Incidence and severity of treatment emergent adverse events and withdrawals due to treatment emergent adverse events",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Incidence and magnitude of treatment emergent clinical laboratory abnormalities including hematology (with white blood cell count differentials, platelets, PT and aPTT), chemistry, fasting glucose, urinalysis",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Change from baseline in immunoglobulin levels",
          "description": "Quantitative IgG, IgA, IgM, and IgE levels",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "24-hour urine creatinine clearance (Single Ascending Dose Period)",
          "timeFrame": "Baseline, Day 1"
        },
        {
          "measure": "24-hour urine creatinine clearance (Multiple Ascending Dose Period)",
          "timeFrame": "Baseline, Day 1"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Complement Level: C3",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Complement Level: C4",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Complement Level: C3A",
          "description": "Cohorts 1-7 and Cohort 9",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Complement Level: Bb",
          "description": "Cohorts 1-7 and Cohort 9",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Infinity (AUCinf(dn))",
          "timeFrame": "8 days"
        },
        {
          "measure": "Multiple Ascending Dose: Accumulation Ratio based on Cmax (Rac(Cmax))",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Urinary Pharmacokinetics; for twice-a-day dosing, amount of PF-0496842 excreted unchanged in 12 hours (AE12)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Urinary Pharmacokinetics; for twice-a-day dosing, percent of PF-0496842 excreted unchanged in 12 hours (AE12%)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Apparent Volume of Distribution at Steady State (Vz/F)",
          "description": "Vz/F is the distribution of a drug between plasma and the rest of the body following oral adminstration.",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Apparent Total Body Clearance (CL/F)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Urinary Pharmacokinetics; for once-a-day dosing, amount of PF-0496842 excreted unchanged in 24 hours (AE24)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Urinary Pharmacokinetics; for once-a-day dosing, percent of PF-0496842 excreted unchanged in 24 hours (AE24%)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Renal Clearance (CLr)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "High-Sensitivity C-Reactive Protein (hsCRP)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Neutrophil counts",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Reticulocyte counts",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Complement Level: CH50",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Single Ascending Dose: Apparent Total Body Clearance (CL/F)",
          "timeFrame": "8 days"
        },
        {
          "measure": "Multiple Ascending Dose: Maximum Observed Plasma Concentration (Cmax)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Time to Reach Maximum Observed Plasma Concentration (Tmax)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau(dn))",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Accumulation Ratio based on AUC predicted (Rss)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Accumulation Ration based on AUC observed (Rac)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Plasma Decay Half-Life (t1/2)",
          "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one-half.",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Multiple Ascending Dose: Peak to Trough Fluctuation (PTF)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Single Ascending Dose: Dose-normalized Area Under the Curve to the end of the dosing period (AUCtau(dn))",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Area Under the Curve From Time Zero to Infinity (AUCinf)",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Dose-normalized Maximum Observed Plasma Concentration (Cmax(dn))",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Dose-normalized Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast(dn))",
          "description": "Dose-normalized area under the plasma concentration time-curve from zero to the last measured concentration (AUClast(dn))",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Plasma Decay Half-Life (t1/2)",
          "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.",
          "timeFrame": "8 days"
        },
        {
          "measure": "Multiple Ascending Dose: Area Under the Curve to the end of the dosing period (AUCtau)",
          "timeFrame": "6 weeks"
        },
        {
          "measure": "Single Ascending Dose: Apparent Volume of Distribution (Vz/F)",
          "timeFrame": "8 days"
        },
        {
          "measure": "Single Ascending Dose: Maximum Observed Plasma Concentration (Cmax)",
          "timeFrame": "8 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.\n* Females must be of non-child bearing potential and either at least 1 year post menopausal (FSH â‰¥40 IU/L), or have documented hysterectomy (with or without bilateral oophrectomy) at least 6 months prior to study day\n* Subjects willing to defer receiving prophylactic immunizations (e.g. influenza or pneumococcal vaccines) during the study.\n* Absolute lymphocyte count must be greater than or equal to the lower limit of the laboratory reference range.\n* Subjects enrolled in Cohort 8 must have four Japanese grandparents born in Japan.\n\nExclusion Criteria:\n\n* Evidence or history of clinically significant hematological, renal, , pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).\n* History of hepatitis or positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBc Ab) or hepatitis C antibodies (HCV).\n* Clinically significant abnormality on chest X-ray performed at screening or within 3 months of screening date; or history of tuberculosis or active or latent or inadequately treated infection.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "55 Years",
      "stdAges": [
        "ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Pfizer CT.gov Call Center",
          "affiliation": "Pfizer",
          "role": "STUDY_DIRECTOR"
        }
      ],
      "locations": [
        {
          "facility": "Pfizer Investigational Site",
          "city": "New Haven",
          "state": "Connecticut",
          "zip": "06511",
          "country": "United States",
          "geoPoint": {
            "lat": 41.30815,
            "lon": -72.92816
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "35061234",
          "type": "DERIVED",
          "citation": "Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022 May;61(5):709-723. doi: 10.1007/s40262-021-01104-z. Epub 2022 Jan 21."
        },
        {
          "pmid": "29672897",
          "type": "DERIVED",
          "citation": "Peeva E, Hodge MR, Kieras E, Vazquez ML, Goteti K, Tarabar SG, Alvey CW, Banfield C. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: A phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol. 2018 Aug;84(8):1776-1788. doi: 10.1111/bcp.13612. Epub 2018 May 24."
        }
      ],
      "seeAlsoLinks": [
        {
          "label": "To obtain contact information for a study center near you, click here.",
          "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7451001&StudyName=First-in-Human%20Study%20to%20Evaluate%20Safety%20and%20Tolerability%20of%20Single%20and%20Multiple%20Ascending%20Doses%20of%20Janus%20Kinase-1%20Inhibitor%20PF-04965842%20in"
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000634427",
          "term": "abrocitinib"
        }
      ]
    }
  },
  "hasResults": false
}